St. Renatus announced that the Food and Drug Administration (FDA) has approved Kovanaze (tetracaine HCl and oxymetazoline HCl) Nasal Spray, the first dental anesthetic administered as a nasal spray. It is delivered in the nasal cavity to achieve pulpal (tooth nerve) anesthesia when performing a restorative procedure on Teeth 4–13 and A–J in patients weighing ≥40kg.
Kovanaze Nasal Spray combines tetracaine HCl, an ester local anesthetic, and oxymetazoline HCl, a vasoconstrictor. Tetracaine HCl works by blocking sodium channels required for the initiation and conduction of neuronal impulses. Oxymetazoline HCl possesses sympathomimetic activity that elicits vasoconstriction of dilated arterioles and reduces nasal blood flow.
Kovanaze Nasal Spray will be available in a 6mg/0.1mg strength as 0.2mL pre-filled, single-use sprays in 30-count boxes.
For more information call (800) 770-9400 or visit St-Renatus.com.